Bifunctional Fusion Molecules for Targeted Interferon Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The systemic use of interferon-alpha (IFN-α) for cancer treatment is limited by its short half-life and associated systemic toxicities, which prevent dosing at levels that maximize anti-proliferative and pro-apoptotic activity on cancer cells.
Innovation Solution
Development of bifunctional fusion molecules comprising mutated polypeptide ligands with reduced biological activity, such as mutated IFN-α, attached to disease tissue-targeting biologics or tumor-associated antigen (TAA)-targeting biologics, which direct the mutated ligands to specific cells expressing the target antigens, thereby reducing off-target activity and toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If interferon-alpha is used systemically for cancer treatment, then anti-proliferative and pro-apoptotic activity on cancer cells is achieved, but systemic toxicities occur and half-life is short
Solution Approach 1:
The interferon-alpha molecule is segmented into two functional components: a mutated ligand domain with reduced biological activity and a targeting domain. This segmentation allows the molecule to separate its anti-proliferative function from its toxicity, enabling targeted delivery to cancer cells while minimizing systemic exposure and toxic effects on healthy cells.
Solution Approach 2:
The bifunctional fusion molecule exhibits local quality by having different functional properties in different regions of the molecule. The mutated ligand domain provides reduced biological activity to minimize toxicity, while the targeting domain provides specificity for cancer cell binding. This local differentiation enables the molecule to exert therapeutic effects locally at the tumor site while avoiding systemic toxicity.
2Reliability
If interferon-alpha is used systemically for cancer treatment, then anti-proliferative and pro-apoptotic activity on cancer cells is achieved, but half-life is short
Solution Approach 1:
The bifunctional fusion molecule merges the mutated ligand domain with the targeting domain into a single integrated molecule. This merging creates a unified therapeutic agent that combines reduced biological activity with targeted delivery capability, thereby extending the effective duration of action by ensuring sustained presence at the tumor site while maintaining anti-proliferative and pro-apoptotic effects.
3Object-affected harmful factors
If mutated IFN-α is used with reduced biological activity, then off-target toxicity is reduced, but activity at target site must be restored
Solution Approach 1:
The targeting domain acts as an intermediary that mediates the delivery of the mutated ligand to the target cancer cells. By binding to specific antigens on the cancer cell surface, the targeting domain restores the biological activity of the mutated ligand at the target site while preventing off-target interactions, thereby resolving the contradiction between reduced toxicity and maintained efficacy.
Data Source
AI summary
The present invention relates to bifunctional fusion molecules comprising a mutated polypeptide ligand (e.g., mutated IFN-α) having reduced biological activity attached to a disease tissue targeting biologic or a tumor associated antigen (TAA)-targeting biologic (e.g., anti-PD-L1 antibody), wherein the targeting biologic or TAA-targeting biologic directs the mutated ligands to cells that express on their surfaces the antigens to which said targeting biologic binds, as well as receptors for said ligands. Importantly, because the mutated polypeptide ligands have reduced biological activity, the resultant fusion molecule have reduced off-target activity/toxicity. More importantly, the targeting of the mutated ligand by the targeting biologic restores the activity of the mutated ligand, with the degree of activity restoration apparently correlated with the level of targeting biologic on the cells. As such, the fusion molecules of the present invention advance the state of art by providing bifunctional fusion molecules having a greater therapeutic window than those previously described. The invention further relates to methods of treating cancer in a patient and in particular, patients with refractory and/or recurrent cancers involving the use of these bifunctional fusion molecules. The invention also relates to methods of treating infectious disease, including but not limited to chronic hepatitis B and C infections in a patient involving the use of these bifunctional fusion molecules.